AYTU BIOPHARMA, INC (AYTU) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
38/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseAYTU / S&P -21.25% / 15.20% |
LoseAYTU / S&P AYTU unavailable / 15.00% |
LoseAYTU / S&P AYTU unavailable / 50.40% |
| 2026-Q11/3 |
WinAYTU / S&P 5.00% / -4.33% |
LoseAYTU / S&P -14.04% / 11.30% |
LoseAYTU / S&P AYTU unavailable / 27.70% |
| 2025-Q41/3 |
WinAYTU / S&P 38.30% / 2.65% |
LoseAYTU / S&P 2.00% / 9.00% |
LoseAYTU / S&P AYTU unavailable / 13.40% |
| 2025-Q30/3 |
LoseAYTU / S&P -13.76% / 8.12% |
LoseAYTU / S&P -0.38% / 4.61% |
LoseAYTU / S&P AYTU unavailable / 13.45% |
| 2025-Q21/3 |
WinAYTU / S&P 81.67% / 10.94% |
LoseAYTU / S&P 1.84% / 4.83% |
LoseAYTU / S&P AYTU unavailable / 10.63% |
| 2025-Q10/3 |
LoseAYTU / S&P -29.41% / -4.27% |
LoseAYTU / S&P -19.04% / 4.98% |
LoseAYTU / S&P AYTU unavailable / 10.57% |
| 2024-Q40/3 |
LoseAYTU / S&P -27.66% / 2.41% |
LoseAYTU / S&P -31.79% / 5.25% |
LoseAYTU / S&P AYTU unavailable / 6.15% |
| 2024-Q30/3 |
LoseAYTU / S&P -19.52% / 5.89% |
LoseAYTU / S&P -34.46% / 5.89% |
LoseAYTU / S&P AYTU unavailable / 6.11% |
| 2024-Q20/3 |
LoseAYTU / S&P -3.95% / 4.28% |
LoseAYTU / S&P -39.31% / 5.38% |
LoseAYTU / S&P AYTU unavailable / 5.12% |
| 2024-Q10/3 |
LoseAYTU / S&P 7.04% / 10.56% |
LoseAYTU / S&P -21.89% / 5.71% |
LoseAYTU / S&P -76.17% / 5.59% |
| 2023-Q40/3 |
LoseAYTU / S&P 5.19% / 11.69% |
LoseAYTU / S&P -14.73% / 6.81% |
LoseAYTU / S&P -91.29% / 7.78% |
| 2023-Q31/3 |
WinAYTU / S&P 68.75% / -3.27% |
LoseAYTU / S&P -4.75% / 7.52% |
LoseAYTU / S&P -88.27% / -5.03% |
| 2023-Q21/3 |
LoseAYTU / S&P -28.57% / 8.74% |
WinAYTU / S&P 11.10% / 9.50% |
LoseAYTU / S&P -90.78% / -8.57% |
| 2023-Q11/3 |
LoseAYTU / S&P -41.05% / 7.50% |
WinAYTU / S&P 12.31% / 10.77% |
LoseAYTU / S&P -77.98% / -15.69% |
| 2022-Q42/3 |
LoseAYTU / S&P 0.00% / 7.56% |
WinAYTU / S&P 28.78% / 11.88% |
WinAYTU / S&P 268.11% / -17.99% |
| 2022-Q32/3 |
LoseAYTU / S&P -72.46% / -4.88% |
WinAYTU / S&P 38.40% / 13.47% |
WinAYTU / S&P 1173.18% / -1.41% |
| 2022-Q22/3 |
LoseAYTU / S&P -36.11% / -16.10% |
WinAYTU / S&P 47.29% / 13.71% |
WinAYTU / S&P 1488.00% / 11.04% |
| 2022-Q11/3 |
LoseAYTU / S&P -20.00% / -4.60% |
WinAYTU / S&P 62.61% / 15.97% |
LoseAYTU / S&P AYTU unavailable / 42.23% |
| 2021-Q41/3 |
LoseAYTU / S&P -53.12% / 11.03% |
WinAYTU / S&P 58.63% / 15.00% |
LoseAYTU / S&P AYTU unavailable / 96.40% |
| 2021-Q31/3 |
LoseAYTU / S&P -42.51% / 0.58% |
WinAYTU / S&P 86.36% / 10.77% |
LoseAYTU / S&P AYTU unavailable / 69.42% |
| 2021-Q21/3 |
LoseAYTU / S&P -34.08% / 8.55% |
WinAYTU / S&P 137.52% / 6.58% |
LoseAYTU / S&P AYTU unavailable / 51.81% |
| 2021-Q12/3 |
WinAYTU / S&P 27.09% / 6.17% |
WinAYTU / S&P 293.38% / -1.06% |
LoseAYTU / S&P AYTU unavailable / 7.39% |
| 2020-Q41/3 |
LoseAYTU / S&P -49.75% / 12.15% |
WinAYTU / S&P 493.51% / -3.72% |
LoseAYTU / S&P AYTU unavailable / -33.42% |
| 2020-Q31/3 |
LoseAYTU / S&P -16.20% / 8.93% |
WinAYTU / S&P 441.92% / -2.04% |
LoseAYTU / S&P AYTU unavailable / -27.10% |
| 2020-Q21/3 |
LoseAYTU / S&P -5.33% / 20.54% |
WinAYTU / S&P 277.49% / -0.46% |
LoseAYTU / S&P AYTU unavailable / -27.11% |
| 2020-Q12/3 |
WinAYTU / S&P 54.64% / -19.60% |
WinAYTU / S&P 122.14% / 3.47% |
LoseAYTU / S&P AYTU unavailable / -14.75% |
| 2019-Q41/3 |
LoseAYTU / S&P -19.83% / 9.07% |
WinAYTU / S&P 82.98% / 5.36% |
LoseAYTU / S&P AYTU unavailable / 2.99% |
| 2019-Q31/3 |
LoseAYTU / S&P -35.98% / 1.70% |
WinAYTU / S&P 82.51% / 5.02% |
LoseAYTU / S&P AYTU unavailable / 0.21% |
| 2019-Q22/3 |
WinAYTU / S&P 13.17% / 4.30% |
WinAYTU / S&P 100.03% / 6.64% |
LoseAYTU / S&P AYTU unavailable / 8.65% |
| 2019-Q12/3 |
WinAYTU / S&P 111.39% / 13.65% |
WinAYTU / S&P 82.72% / 8.12% |
LoseAYTU / S&P AYTU unavailable / 14.29% |
| 2018-Q41/3 |
LoseAYTU / S&P -71.38% / -13.52% |
WinAYTU / S&P 23.39% / 9.05% |
LoseAYTU / S&P AYTU unavailable / 18.23% |
| 2018-Q31/3 |
LoseAYTU / S&P -46.92% / 7.71% |
WinAYTU / S&P 11.53% / 10.21% |
LoseAYTU / S&P AYTU unavailable / 19.06% |
| 2018-Q21/3 |
LoseAYTU / S&P -59.38% / 3.43% |
WinAYTU / S&P 13.59% / 9.03% |
LoseAYTU / S&P AYTU unavailable / 14.46% |
| 2018-Q10/3 |
LoseAYTU / S&P -71.30% / -0.76% |
LoseAYTU / S&P 5.41% / 7.68% |
LoseAYTU / S&P AYTU unavailable / 12.46% |
| 2017-Q41/3 |
LoseAYTU / S&P -44.25% / 6.64% |
WinAYTU / S&P 22.81% / 7.03% |
LoseAYTU / S&P AYTU unavailable / 13.82% |
| 2017-Q31/3 |
LoseAYTU / S&P -66.10% / 4.48% |
WinAYTU / S&P 28.83% / 5.68% |
LoseAYTU / S&P AYTU unavailable / 17.57% |
| 2017-Q21/3 |
LoseAYTU / S&P -34.44% / 3.09% |
WinAYTU / S&P 25.72% / 4.83% |
LoseAYTU / S&P AYTU unavailable / 17.74% |
| 2017-Q11/3 |
LoseAYTU / S&P -25.00% / 6.07% |
WinAYTU / S&P 87.36% / 3.67% |
LoseAYTU / S&P AYTU unavailable / 13.32% |
| 2016-Q41/3 |
LoseAYTU / S&P -63.19% / 3.82% |
WinAYTU / S&P 170.09% / 2.09% |
LoseAYTU / S&P AYTU unavailable / 7.05% |
| 2016-Q31/3 |
LoseAYTU / S&P -30.34% / 3.85% |
WinAYTU / S&P 287.16% / 0.20% |
LoseAYTU / S&P AYTU unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AYTU total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -4.68% | 20.78% |
| Annualized return | -4.68% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AYTU total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.08% | 83.14% |
| Annualized return | -50.66% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | AYTU total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -69.41% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |